* * *	* *	* *	* *	* Welcome to STN International * * * * * * * * *
NEWS NEWS	1 2	OCT	02	Web Page for STN Seminar Schedule - N. America CA/CAplus enhanced with pre-1907 records from Chemisches
NEWS	3	OCT	10	Zentralblatt BEILSTEIN updated with new compounds
NEWS		NOV		Derwent Indian patent publication number format enhanced
NEWS		NOV		WPIX enhanced with XML display format
NEWS		NOV		ICSD reloaded with enhancements
NEWS			0.4	LINPADOCDB now available on STN
NEWS	8	DEC	14	BEILSTEIN pricing structure to change
NEWS	9	DEC	17	USPATOLD added to additional database clusters
NEWS	10	DEC	17	IMSDRUGCONF removed from database clusters and STN
NEWS	11	DEC	17	DGENE now includes more than 10 million sequences
NEWS	12	DEC	17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	13			MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS			17	CA/CAplus enhanced with new custom IPC display formats
NEWS	15	DEC	17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS		JAN		STN pricing information for 2008 now available
NEWS	17	JAN	16	CAS patent coverage enhanced to include exemplified
NEWS	18	JAN	28	prophetic substances USPATFULL, USPAT2, and USPATOLD enhanced with new
				custom IPC display formats
NEWS		JAN		MARPAT searching enhanced
NEWS	20	JAN	28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	21	JAN	28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS		JAN		MEDLINE and LMEDLINE reloaded with enhancements
NEWS				STN Express, Version 8.3, now available
NEWS				PCI now available as a replacement to DPCI
NEWS				IFIREF reloaded with enhancements
NEWS				IMSPRODUCT reloaded with enhancements
NEWS	27	FEB	29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	EXP	RESS		RUARY 08 CURRENT WINDOWS VERSION IS V8.3, CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008
NEWS	пош	D.C.	CTI	V Operating Hours Plus Help Desk Availability
NEWS				come Banner and News Items
NEWS				general information regarding STN implementation of IPC 8
Enter speci:				ed by the item number or name to see news on that
7.1.7	1100	of s	TNI -	is subject to the provisions of the STM Custor
agre rese of o	eemen earch	nt. h. (ercia	Plea Jse :	is subject to the provisions of the STN Customer sae note that this agreement limits use to scientific for software development or design or implementation ateways or other similar uses is prohibited and may for user privileges and other penalties.

* * * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

1c

FILE 'HOME' ENTERED AT 13:57:13 ON 11 MAR 2008

=> file caplus

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION

0.21

0.21

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 13:57:56 ON 11 MAR 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Mar 2008 VOL 148 ISS 11 FILE LAST UPDATED: 10 Mar 2008 (20080310/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s direct (5a) compress? (5a) tablet

667220 DIRECT

9027 DIRECTS

675195 DIRECT (DIRECT OR DIRECTS)

319979 COMPRESS?

54878 TABLET

82646 TABLETS

97245 TABLET

(TABLET OR TABLETS)

L1 1076 DIRECT (5A) COMPRESS? (5A) TABLET

=> s 11 and ad<20001229

3926960 AD<20001229

(AD<20001229)

2 112 L1 AND AD<20001229

=> s 12 and dextrose monohydrate

19155 DEXTROSE

11 DEXTROSES 19160 DEXTROSE

(DEXTROSE OR DEXTROSES)

28917 MONOHYDRATE

837 MONOHYDRATES

29433 MONOHYDRATE

(MONOHYDRATE OR MONOHYDRATES)

160 DEXTROSE MONOHYDRATE

(DEXTROSE(W)MONOHYDRATE)
L3 0 L2 AND DEXTROSE MONOHYDRATE

=> s 12 and dextrose

19155 DEXTROSE

11 DEXTROSES

19160 DEXTROSE

(DEXTROSE OR DEXTROSES)

L4 4 L2 AND DEXTROSE

=> d 14 ibib kwic 1-

YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:185548 CAPLUS <<LOGINID::20080311>>

DOCUMENT NUMBER: 134:227386

TITLE: Sugar compositions for tableting containing amorphous

particulate trehalose

INVENTOR(S): James, Martin John; Heath, Christopher; Sistern, Hugh

PATENT ASSIGNEE(S): British Sugar PLC, UK SOURCE: PCT Int. Appl., 16 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English FAMILY ACC. NUM. COUNT: 1

| | | ENT : | | | | | | DATE | | | | | | | | | ATE | |
|------|------|--------------------|---------------------------------|---------------------------------|---------------------------------|--------------------------|--------------------------|---------------------------------|--------------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
| | WO | 2001 | 0175 | 03 | | | | | | | WO 2 | | | | | | 0000 | 907 < |
| | | | AE,
CR,
HU,
LU,
SD, | AG,
CU,
ID,
LV,
SE, | AL,
CZ,
IL,
MA,
SG, | AM,
DE,
IN,
MD, | AT,
DK,
IS,
MG, | AU,
DM,
JP,
MK,
SL, | AZ,
DZ,
KE,
MN, | EE,
KG,
MW, | ES,
KP,
MX, | FI,
KR,
MZ, | GB,
KZ,
NO, | GD,
LC,
NZ, | GE,
LK,
PL, | GH,
LR,
PT, | GM,
LS,
RO, | HR,
LT,
RU, |
| | | RW: | GH,
DE, | DK, | KE,
ES, | FΙ, | FR, | MZ,
GB,
GN, | GR, | IE, | ΙT, | LU, | MC, | NL, | PT, | | | |
| PRIO | RIT: | 2353
APP
ENT | LN.
NO. | INFO | .: | KIN | D | 2001
DATE | | | GB 1 | 999-
ICAT | 2133
ION : | 5
NO. | | A 1: | | |
| PI | | 2001
2001 | | | | | | | | | WO 2 | 000- | GB34 | 36 | | 2 | 0000 | 907 < |
| | | W: | CR,
HU,
LU, | CU,
ID,
LV, | CZ,
IL,
MA, | DE,
IN,
MD, | DK,
IS,
MG, | AU,
DM,
JP,
MK,
SL, | DZ,
KE,
MN, | EE,
KG,
MW, | ES,
KP,
MX, | FI,
KR,
MZ, | GB,
KZ,
NO, | GD,
LC,
NZ, | GE,
LK,
PL, | GH,
LR,
PT, | GM,
LS,
RO, | HR,
LT,
RU, |

YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FT, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
2353933 A 20101314 GB 1999-21335 19990909 <--

AB . . . major fraction of powdered sucrose. Preferably, the amorphous trehalose is a spray dried. Also provided are methods of manufacturing a tablet by direct compression of the compns., and tablets obtainable thereby.

50-99-7, Dextrose, biological studies 57-48-7, Fructose, biological studies 57-50-1, Sucrose, biological studies 63-42-3, Lactose 69-79-4, Maltose 99-20-7, Trehalose 6138-23-4, Trehalose dihydrate

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (sugar compns. for tableting containing amorphous particulate trehalose)

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:776656 CAPLUS <<LOGINID::20080311>>

DOCUMENT NUMBER: 130:29239

TITLE: Fast-dissolving tablets and methods of their

manufacture by direct compression INVENTOR(S): Eoga, Anthony B. J.; Valia, Kirti H.

PATENT ASSIGNEE(S): Warner-Lambert Co., USA SOURCE: PCT Int. Appl., 34 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English FAMILY ACC. NUM. COUNT: 1

| | | ENT: | | | | | | | | | | | | | | | ATE | |
|------|---------|-------|------|------|-----|-----|-----|------|-------|------|------|------|------|-------|------|------|-------|--------|
| | | 9852 | 541 | | | A1 | | 1998 | 1126 | | WO 1 | 998- | US88 | 21 | | 1 | | 504 < |
| | | ₩: | | | | | | BR, | | | | | | | | | | |
| | | | JP, | KR, | LC, | LK, | LR, | LT, | LV, | MG, | MK, | MN, | MX, | NO, | NZ, | PL, | RO, | SG, |
| | | | SI, | SK, | SL, | TR, | TT, | UA, | US, | UZ, | VN, | YU, | AM, | AZ, | BY, | KG, | KZ, | MD, |
| | | | RU, | TJ, | TM | | | | | | | | | | | | | |
| | | RW: | GH, | GM, | KE, | LS, | MW, | SD, | SZ, | UG, | ZW, | ΑT, | BE, | CH, | CY, | DE, | DK, | ES, |
| | | | FI, | FR, | GB, | GR, | ΙE, | IT, | LU, | MC, | NL, | PT, | SE, | BF, | ВJ, | CF, | CG, | CI, |
| | | | CM, | | | | | NE, | | | | | | | | | | |
| | US | 5939 | 091 | | | A | | 1999 | 0817 | | US 1 | 998- | 4074 | 9 | | 1 | 9980: | 318 < |
| | | | | | | | | | | | | | | | | | | 504 < |
| | z_{A} | 9804 | 229 | | | A | | 1999 | 1119 | | | | | | | | | 519 < |
| PRIO | RIT | APP | LN. | INFO | . : | | | | | | US 1 | 997- | 4721 | 7P | | P 1 | 9970: | 520 |
| | | | | | | | | | | | WO 1 | 998- | US88 | 21 | | W 1 | 9980 | 504 |
| REFE | RENO | CE CO | UNT: | | | 4 | T | HERE | ARE | 4 C | ITED | REF. | EREN | CES . | AVAI | LABL | E FO | R THIS |
| | | | | | | | R | ECOR | D. A: | LL C | ITAT | IONS | AVA | ILAB | LE I | N TH | E RE | FORMAT |
| | | ENT : | | | | | | DATE | | | | | | | | | ATE | |
| PI | | 9852 | | | | | | | | | | | | | | | 9980 | 504 < |
| | | W: | AL. | AU. | BA. | BB. | BG. | BR, | CA. | CN. | CZ. | EE. | GE. | GW. | HU. | ID. | IL. | IS. |
| | | | | | | | | LT, | | | | | | | | | | |
| | | | | | | | | UA, | | | | | | | | | | |
| | | | | TJ. | | , | -, | | - / | -, | | - / | | | -, | | | |
| | | RW: | | | | LS. | MW. | SD, | SZ. | UG. | ZW. | AT. | BE. | CH. | CY. | DE. | DK. | ES. |
| | | | | | | | | IT, | | | | | | | | | | |
| | | | / | / | , | / | , | / | , | / | | / | | / | , | / | , | , |

CM, GA, GN, ML, MR, NE, SN, TD, TG US 593991 A 1999817 US 1998-40749 19980318 <-AU 9871726 A 19981211 AU 1998-71726 19980504 <-22 9804229 A 19991119 ZA 1998-4229 19980519 <--

ST pharmaceutical tablet direct compression

density; alk earth metal salt pharmaceutical tablet

50-70-4, Sorbitol, biological studies 50-99-7, Dextrose, biological studies 57-50-1, Sucrose, biological studies 69-65-8, Mannitol 69-79-4, Maltose 87-99-0, Xylitol 471-34-1, Calcium carbonate, biological studies 546-93-0, Magnesium carbonate 585-88-6, Maltitol 1305-62-0, Calcium hydroxide, biological studies 1309-42-8, Magnesiumhydroxide 1343-88-0, Magnesium silicate 11137-98-7, Magnesium aluminate 21645-51-2, Aluminum hydroxide, biological studies 39366-43-3, Aluminum magnesiumhydroxide

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (fast-dissolving tablets and methods of their manufacture by direct compression)

ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1987:561691 CAPLUS <<LOGINID::20080311>> DOCUMENT NUMBER: 107:161691

TITLE:

Improvements in and relating to effervescent

acetylsalicylic acid tablets

INVENTOR(S): Jones, Stephen Keith; Wilson, Peter David Nicholas Pty. Ltd., Australia PATENT ASSIGNEE(S):

SOURCE: Eur. Pat. Appl., 26 pp.

CODEN: EPXXDW DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|------------------------|----------|----------------------|-------------------|----|------------|
| | A2
A3 | 19870422
19870916 | EP 1986-307908 | - | 19861013 < |
| R: AT, BE, CH, | DE, ES, | FR, GR, IT | r, LI, LU, NL, SE | | |
| GB 2189700 | | 19871104 | GB 1986-24520 | | 19861013 < |
| GB 2189700 | В | | | | |
| WO 8702242 | | 19870423 | WO 1986-AU304 | | 19861014 < |
| W: AU, DK, FI, | | | | | |
| AU 8665290 | | 19870505 | AU 1986-65290 | | 19861014 < |
| | | 19900823 | | | |
| JP 63501505 | | 19880609 | JP 1986-505526 | | 19861014 < |
| JP 07008797 | | 19950201 | | | |
| CA 1275252 | | 19901016 | CA 1986-520413 | | 19861014 < |
| ZA 8607816 | | 19870624 | ZA 1986-7816 | | 19861015 < |
| NO 8702425 | | 19870610 | NO 1987-2425 | | 19870610 < |
| DK 8703020 | | 19870612 | DK 1987-3020 | | 19870612 < |
| FI 8702638 | | 19870612 | FI 1987-2638 | | 19870612 < |
| US 5037657 | A | 19910806 | US 1990-491739 | | 19900312 < |
| PRIORITY APPLN. INFO.: | | | GB 1985-25348 | | 19851015 |
| | | | WO 1986-AU304 | | 19861014 |
| | | | US 1987-86089 | В1 | 19870915 |
| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
| | | | | - | |

```
PI EP 219337
                        A2 19870422 EP 1986-307908
A3 19870916
                                                                  19861013 <--
     EP 219337
        R: AT, BE, CH, DE, ES, FR, GR, IT, LI, LU, NL, SE
     GB 2189700 A 19871104
                                          GB 1986-24520
                                                                  19861013 <--
                        B 19891018
A1 19870423
     GB 2189700
     WO 8702242
                                          WO 1986-AU304
                                                                  19861014 <--
        W: AU, DK, FI, JP, KR, NO, US
                             19870505
    AU 8665290 A
                                         AU 1986-65290
                                                                  19861014 <--
    AU 600687
                        B2
                              19900823
                       T 19880609 JP 1986-505526
B 19950201
    JP 63501505
                                                                 19861014 <--
                       B 19950201
C 19901016 CA 1986-520413
A 19870624 ZA 1986-7816
A 19870610 NO 1987-2425
    JP 07008797
    CA 1275252
                                                                  19861014 <--
     ZA 8607816
                                                                  19861015 <--
    NO 8702425
                                                                 19870610 <--
    DK 8703020
                        A
                              19870612 DK 1987-3020
                                                                 19870612 <--
    FI 8702638
US 5037657
                        A 19870612 FI 1987-2638
A 19910806 US 1990-491739
                                                                 19870612 <--
                                                                 19900312 <--
AB
    Dextrose and/or sucrose are used as disintegrants or dissoln.
    aids in effervescent tablets of acetylsalicylic acid (I), which are formed
     by direct compression. An effervescent I tablet was produced by
     direct compression of the dry powder mixture containing coated
     I 350, NaHCO3 439, Na2CO3 24, citric acid 240, and spray-crystallized
    dextrose 400 mg. Control tablets contained no dextrose.
     The inclusion of dextrose gave faster dissoln, times both
     initially and after 12 wk storage at 20° or 40°, at hardness
    ranges of 4-6. . .
ST
    aspirin tablet effervescent sucrose dextrose; acetylsalicylate
    tablet effervescent sucrose dextrose; disintegrator sucrose
    dextrose aspirin effervescent tablet
   Pharmaceutical dosage forms
       (tablets, effervescent, of aspirin, dextrose or sucrose in,
       as disintegrator)
    50-99-7, Dextrose, biological studies 57-50-1, biological
     studies
     RL: BIOL (Biological study)
       (effervescent aspirin tablets containing spray crystallized, as
disintegrator)
    50-78-2, Acetylsalicylic acid
     RL: PROC (Process)
        (effervescent tablet formulation of, dextrose in, as
       disintegrator)
L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1972:61236 CAPLUS <<LOGINID::20080311>> DOCUMENT NUMBER: 76:61236
ORIGINAL REFERENCE NO.: 76:9877a,9880a
TITLE:
                       Compressed tablets containing dextrose
INVENTOR(S):
                       Brouillard, Robert E.; Griffith, Charles L.
                      Penick and Ford, Ltd., Inc.
PATENT ASSIGNEE(S):
                        U.S., 6 pp.
SOURCE:
                        CODEN: USXXAM
DOCUMENT TYPE:
                        Patent
LANGUAGE:
                        English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:
```

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|-------------------------|----------|----------------------|--|-------------|
| | | | | | |
| | US 3619292 | A | | US 1968-744645 | |
| | DK 125824 | В | 19730514 | DK 1969-3481 | 19690627 < |
| | FR 2012974 | A5 | 19700327 | FR 1969-23744 | 19690711 < |
| | ES 369431 | A1 | 19710601 | ES 1969-369431 | |
| | CA 943064 | A1 | 19740305 | CA 1969-56801 | 19690711 < |
| | CH 521720 | A | 19720430 | CH 1969-521720 | 19690714 < |
| | GB 1275086 | A | 19720524 | GB 1969-1275086 | |
| | BE 736100 | A | 19691216 | BE 1969-736100
NL 1969-10896 | 19690715 < |
| | NL 6910896 | A
A | 19700119 | NL 1969-10896 | 19690715 < |
| | DE 1935891 | A | 19700122 | DE 1969-1935891 | 19690715 < |
| | DE 1935891 | B2 | | | |
| | DE 1935891 | C3 | 19731213 | | |
| | RITY APPLN. INFO.: | | | | 19680715 |
| TI | Compressed tablets | | | | |
| | PATENT NO. | KIND | DATE | APPLICATION NO. | |
| | | | | | |
| PΙ | US 3619292 | A | 19711109 | | 19680715 < |
| | DK 125824
FR 2012974 | В | 19730514 | DK 1969-3481
FR 1969-23744 | 19690627 < |
| | | | | FR 1969-23744 | 19690711 < |
| | ES 369431 | A1 | 19710601 | ES 1969-369431 | 19690711 < |
| | CA 943064 | A1
A | 19740305 | CA 1969-56801
CH 1969-521720 | 19690711 < |
| | CH 521720 | A | 19720430 | | |
| | GB 1275086 | A | 19720524 | GB 1969-1275086 | 19690714 < |
| | BE 736100 | A | 19691216
19700119 | GB 1969-1275086
BE 1969-736100
NL 1969-10896 | 19690715 < |
| | NL 6910896 | A | 19700119 | NL 1969-10896 | 19690715 < |
| | DE 1935891 | | | DE 1969-1935891 | 19690715 < |
| | DE 1935891 | B2 | 19730510 | | |
| | DE 1935891 | C3 | 19731213 | | |
| AB | | | |) granules are used as | a binder or |
| | binder-filler in m | | | | |
| | preferably by dire | | | | |
| | | | | 'S granules have been b | |
| | | | | carrier, and/or as a | |
| | | | | anules of high dextros | |
| | | | | pherical aggregates of | |
| | | | | ontaining the residual | |
| | | | | sis in solid solution, | |
| | being free-flowing | , nonhyq | groscopic, po | rous, and compressible | . Thus |
| | | | | otal corn sugar (92-3% | |
| | | | | % Mg stearate powder, | which was |
| | added as a lubrica | | | | |
| ST | dextrose tableting | compn; | sugar tablet | ing compn | |
| | | | | | |

```
=> s chewable (5a) tablet
1658 CHEWABLE
```

¹¹ CHEWABLES

¹⁶⁶⁰ CHEWABLE

⁽CHEWABLE OR CHEWABLES)

⁵⁴⁸⁷⁸ TABLET

⁸²⁶⁴⁶ TABLETS 97245 TABLET

⁽TABLET OR TABLETS)

L5 1312 CHEWABLE (5A) TABLET

=> s chewable (5a) tablet and desxtrose

```
1658 CHEWABLE
           11 CHEWABLES
          1660 CHEWABLE
                (CHEWABLE OR CHEWABLES)
         54878 TABLET
         82646 TABLETS
        97245 TABLET
                (TABLET OR TABLETS)
          1312 CHEWABLE (5A) TABLET
            0 DESXTROSE
1.6
            0 CHEWABLE (5A) TABLET AND DESXTROSE
=> s chewable (5a) tablet and dextrose
          1658 CHEWARLE
           11 CHEWABLES
          1660 CHEWABLE
                (CHEWABLE OR CHEWABLES)
         54878 TABLET
         82646 TABLETS
        97245 TABLET
                (TABLET OR TABLETS)
         1312 CHEWABLE (5A) TABLET
         19155 DEXTROSE
           11 DEXTROSES
         19160 DEXTROSE
               (DEXTROSE OR DEXTROSES)
           53 CHEWABLE (5A) TABLET AND DEXTROSE
L7
=> s chewable (5a) tablet and dextrose and direct (3a) compression
          1658 CHEWABLE
           11 CHEWABLES
          1660 CHEWABLE
                (CHEWABLE OR CHEWABLES)
         54878 TABLET
         82646 TABLETS
        97245 TABLET
                (TABLET OR TABLETS)
         1312 CHEWABLE (5A) TABLET
         19155 DEXTROSE
           11 DEXTROSES
         19160 DEXTROSE
                (DEXTROSE OR DEXTROSES)
        667220 DIRECT
         9027 DIRECTS
        675195 DIRECT
                 (DIRECT OR DIRECTS)
        132237 COMPRESSION
          1404 COMPRESSIONS
        132907 COMPRESSION
                 (COMPRESSION OR COMPRESSIONS)
          2246 DIRECT (3A) COMPRESSION
L8
            2 CHEWABLE (5A) TABLET AND DEXTROSE AND DIRECT (3A) COMPRESSION
=> s chewable (5a) tablet and dextrose and direct (3a) compression and ad<20001229
```

1.9

T. 9

AN

DN

TI

DT

LA

PΤ

```
1658 CHEWABLE
           11 CHEWABLES
          1660 CHEWABLE
                (CHEWABLE OR CHEWABLES)
         54878 TABLET
         82646 TABLETS
         97245 TABLET
                (TABLET OR TABLETS)
         1312 CHEWABLE (5A) TABLET
         19155 DEXTROSE
           11 DEXTROSES
         19160 DEXTROSE
                (DEXTROSE OR DEXTROSES)
        667220 DIRECT
         9027 DIRECTS
        675195 DIRECT
                (DIRECT OR DIRECTS)
        132237 COMPRESSION
          1404 COMPRESSIONS
        132907 COMPRESSION
                (COMPRESSION OR COMPRESSIONS)
          2246 DIRECT (3A) COMPRESSION
       3926960 AD<20001229
                (AD<20001229)
             1 CHEWABLE (5A) TABLET AND DEXTROSE AND DIRECT (3A) COMPRESSION
               AND AD<20001229
=> d 19
   ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN
   1970:103755 CAPLUS <<LOGINID::20080311>>
    72:103755
OREF 72:18837a,18840a
    Tablets
IN Brouillard, Robert E.; Griffith, Charles L.
PA Penick and Ford, Ltd., Inc.
SO Ger. Offen., 27 pp.
    CODEN: GWXXBX
    Patent
    German
FAN.CNT 2
     PATENT NO.
                  KIND DATE APPLICATION NO. DATE
                        ----
                        A
                              19700122
    DE 1935891
                                          DE 1969-1935891
                                                                 19690715 <--
DE 193891 B2 19730510

DE 193891 C3 19731213

US 3619292 A 19711109

PRAI US 1968-744645 A 19680715
                              19711109 US 1968-744645 19680715 <--
=> d his full
     (FILE 'HOME' ENTERED AT 13:57:13 ON 11 MAR 2008)
     FILE 'CAPLUS' ENTERED AT 13:57:56 ON 11 MAR 2008
          1076 SEA ABB=ON PLU=ON DIRECT (5A) COMPRESS? (5A) TABLET
```

```
112 SEA ABB=ON PLU=ON L1 AND AD<20001229
1.3
             0 SEA ABB=ON PLU=ON L2 AND DEXTROSE MONOHYDRATE
             4 SEA ABB=ON PLU=ON L2 AND DEXTROSE
L4
               D L4 IBIB KWIC 1-
L5
          1312 SEA ABB=ON PLU=ON CHEWABLE (5A) TABLET
L6
            O SEA ABB=ON PLU=ON CHEWABLE (5A) TABLET AND DESXTROSE
L7
            53 SEA ABB=ON PLU=ON CHEWABLE (5A) TABLET AND DEXTROSE
             2 SEA ABB=ON PLU=ON CHEWABLE (5A) TABLET AND DEXTROSE AND
L8
               DIRECT (3A) COMPRESSION
L9
             1 SEA ABB=ON PLU=ON CHEWABLE (5A) TABLET AND DEXTROSE AND
               DIRECT (3A) COMPRESSION AND AD<20001229
               D T.9
```

FILE HOME

FILE CAPLUS

=> s 14 and sucralose

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on SIN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

```
FILE COVERS 1907 - 11 Mar 2008 VOL 148 ISS 11 FILE LAST UPDATED: 10 Mar 2008 (20080310/ED)
```

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

0 L4 AND SACCHARIN

=> s (12 or 17) and sucralose 1235 SUCRALOSE

1235 SUCRALOSE

L12 14 (L2 OR L7) AND SUCRALOSE

=> d 112 ibib kwic 1-YOU HAVE REQUESTED DATA FROM 14 ANSWERS - CONTINUE? Y/(N):Y

L12 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2007:1092492 CAPLUS <<LOGINID::20080311>>

DOCUMENT NUMBER: 147:392459

TITLE: Taste masked pharmaceutical composition comprising water insol. polymer for oral solid dosage form and

process for preparing the same

INVENTOR(S): Kashid, Namdev; Chouhan, Pradeep; Mukherji, Gour

PATENT ASSIGNEE(S): Jubilant Organosys Limited, India

SOURCE: PCT Int. Appl., 27pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English

LANGUAGE: E: FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| | PAT | ENT I | MO. | | | KIN | D | DATE | | | APPL | ICAT | ION : | NO. | | D. | ATE | |
|-------|------|-------|------|------|-----|-----|-----|------|------|-----|------|-------|-------|-----|-----|-----|------|-----|
| | | | | | | | _ | | | | | | | | | | | |
| | WO | 20073 | 1080 | 10 | | A2 | | 2007 | 0927 | | WO 2 | 007- | IN10 | 9 | | 2 | 0070 | 319 |
| | | W: | ΑE, | AG, | AL, | AM, | ΑT, | AU, | AZ, | BA, | BB, | BG, | BH, | BR, | BW, | BY, | BZ, | CA |
| | | | CH, | CN, | CO, | CR, | CU, | CZ, | DE, | DK, | DM, | DZ, | EC, | EE, | EG, | ES, | FI, | GB |
| | | | GD, | GE, | GH, | GM, | GT, | HN, | HR, | HU, | ID, | IL, | IN, | IS, | JP, | KE, | KG, | KM |
| | | | KN, | KP, | KR, | KZ, | LA, | LC, | LK, | LR, | LS, | LT, | LU, | LY, | MA, | MD, | MG, | MK |
| | | | MN, | MW, | MX, | MY, | MZ, | NA, | NG, | NI, | NO, | NZ, | OM, | PG, | PH, | PL, | PT, | RO |
| | | | RS, | RU, | SC, | SD, | SE, | SG, | SK, | SL, | SM, | SV, | SY, | TJ, | TM, | TN, | TR, | TT |
| | | | TZ, | UA, | UG, | US, | UZ, | VC, | VN, | ZA, | ZM, | ZW | | | | | | |
| | | RW: | AT, | BE, | BG, | CH, | CY, | CZ, | DE, | DK, | EE, | ES, | FI, | FR, | GB, | GR, | HU, | ΙE |
| | | | IS, | IT, | LT, | LU, | LV, | MC, | MT, | NL, | PL, | PT, | RO, | SE, | SI, | SK, | TR, | BF |
| | | | ВJ, | CF, | CG, | CI, | CM, | GA, | GN, | GQ, | GW, | ML, | MR, | NE, | SN, | TD, | TG, | BW |
| | | | GH, | GM, | KE, | LS, | MW, | MZ, | NA, | SD, | SL, | SZ, | TZ, | UG, | ZM, | ZW, | AM, | AZ |
| | | | BY, | KG, | KZ, | MD, | RU, | TJ, | TM | | | | | | | | | |
| | IN | 20061 | DE00 | 752 | | A | | 2007 | 0928 | | IN 2 | 006-1 | DE75 | 2 | | 2 | 0060 | 321 |
| PRIOR | RITY | APPI | LN. | INFO | . : | | | | | | IN 2 | 006-1 | DE75 | 2 | | A 2 | 0060 | 321 |
| - m | Ob - | | | | | | | | | | | | | | | | | |

IT Chewable drug delivery systems

Pharmaceutical tablets

(chewable tablets; taste masked pharmaceutical

composition comprising water insol. polymer for oral solid dosage form and process for preparing same)

process for preparing same) 50-70-4, Sorbitol, biological studies 50-99-7, Dextrose, biological studies 57-11-4, Stearic acid, biological studies 57-50-1, Sucrose, biological studies 63-42-3, Lactose 69-65-8, Mannitol 79-41-4D, Methacrylic acid, copolymer 87-99-0, Xylitol 144-55-8, Sodium bicarbonate, biological studies 151-21-3, Sodium lauryl sulfate, biological studies 497-19-8, Sodium carbonate, biological studies 546-93-0, Magnesium carbonate 557-04-0, Magnesium stearate 585-88-6, Maltitol 1327-43-1, Magnabrite F 1338-39-2, Sorbitan monolaurate 1338-41-6, Sorbitan monostearate 1592-23-0, Calcium stearate 4070-80-8, Sodium stearyl fumarate 7631-86-9, Silica, biological studies 7647-14-5, Sodium chloride, biological studies 7757-93-9, Dibasic calcium phosphate 7758-87-4, Tribasic calcium phosphate 7778-18-9, Calcium sulfate 9000-30-0, Guar gum 9000-65-1, Tragacanth 9000-69-5, Pectin 9002-89-5, Polyvinyl alcohol 9003-39-8, Polyvinylpyrrolidone 9004-32-4, Carboxymethyl cellulose 9004-34-6, Cellulose, biological studies 9004-38-0, Cellulose acetate phthalate 9004-53-9, Dextrin 9004-57-3, Ethvl cellulose 9004-62-0, Hydroxyethyl cellulose 9004-65-3, Hydroxypropyl methylcellulose 9004-67-5, Methylcellulose 9005-25-8, Starch, biological studies 9005-38-3, Sodium alginate 9005-65-6, Polysorbate 80 9049-76-7, Hydroxypropyl starch 9050-04-8, Calcium carboxymethylcellulose 9050-31-1, Hydroxypropylmethyl cellulose

phthalate 14807-96-6, Talc, biological studies 14987-04-3, Magnesium trisilicate 22839-47-0, Aspartame 24938-16-7, Eudragit EPO 25322-68-3, Polyethylene glycol 26266-57-9, Sorbitan monopalmitate 31566-31-1, Glyceryl monostearate 34552-83-5, Loperamide hydrochloride 52907-01-4, Cellulose acetate trimellitate 53179-11-6, Loperamide 53237-50-6 55589-62-3, Acesulfame potassium 56038-13-2, Sucralose 71138-97-1, Hydroxypropylmethyl cellulose acetate succinate 79794-75-5, Loratidine 83799-24-0, Fexofenadine 84057-84-1, Lamotrigine 99614-02-5, Ondansetron 100643-71-8, Desloratadine 103628-46-2, Sumatriptan 106266-06-2, Risperidone 106392-12-5, Polyoxyethylenepolyoxypropylene block copolymer 109889-09-0, Granisetron 121679-13-8, Naratriptan 132539-06-1, Olanzapine 158966-92-8, Montelukast 434943-29-0, Pearlitol 300DC RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(taste masked pharmaceutical composition comprising water insol. polymer for oral solid dosage form and process for preparing same)

L12 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2007:873790 CAPLUS <<LOGINID::20080311>>

DOCUMENT NUMBER: 147:219439

TITLE: Calcium phosphate salts in dentifrice oral compositions suitable as a tooth remineralizing agent

INVENTOR(S): Haas, Michael S.; Greenberg, Michael J.

PATENT ASSIGNEE(S): Wm. Wrigley Jr. Company, USA

SOURCE: U.S. Pat. Appl. Publ., 16pp. CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| | PATE | ENT | NO. | | | KIN | D | DATE | | | APPL | ICAT | ION : | . OV | | D. | ATE | |
|------|------|------|--------------|------|------|------|------|------|-------|------|------|------|-------|------|-------|------|------|------|
| | | | 1839
0927 | | | | | 2007 | | | | | | | | | | |
| | | W: | | | | | | AU, | | | | | | | | | | |
| | | | | | | | | DE, | | | | | | | | | | |
| | | | GE, | GH, | GM, | GT, | HN, | HR, | HU, | ID, | IL, | IN, | IS, | JP, | KE, | KG, | KM, | KN, |
| | | | KP, | KR, | KZ, | LA, | LC, | LK, | LR, | LS, | LT, | LU, | LV, | LY, | MA, | MD, | MG, | MK, |
| | | | MN, | MW, | MX, | MY, | MZ, | NA, | NG, | NI, | NO, | NZ, | OM, | PG, | PH, | PL, | PT, | RO, |
| | | | RS, | RU, | SC, | SD, | SE, | SG, | SK, | SL, | SM, | SV, | SY, | ΤJ, | TM, | TN, | TR, | TT, |
| | | | TZ, | UA, | UG, | US, | UZ, | VC, | VN, | ZA, | ZM, | ZW | | | | | | |
| | | RW: | AT, | BE, | BG, | CH, | CY, | CZ, | DE, | DK, | EE, | ES, | FI, | FR, | GB, | GR, | HU, | IE, |
| | | | IS, | IT, | LT, | LU, | LV, | MC, | NL, | PL, | PT, | RO, | SE, | SI, | SK, | TR, | BF, | ΒJ, |
| | | | CF, | CG, | CI, | CM, | GΑ, | GN, | GQ, | GW, | ML, | MR, | NE, | SN, | TD, | TG, | BW, | GH, |
| | | | GM, | KE, | LS, | MW, | MZ, | NA, | SD, | SL, | SZ, | TZ, | UG, | ZM, | ZW, | AM, | AZ, | BY, |
| | | | KG, | KZ, | MD, | RU, | TJ, | TM | | | | | | | | | | |
| | US 2 | 2008 | 0504 | 07 | | A1 | | 2008 | 0228 | | JS 2 | 007- | 6707 | 37 | | 2 | 0070 | 202 |
| PRIC | RITY | APP | LN. | INFO | . : | | | | | | JS 2 | 006- | 7652 | 89P | 1 | P 2 | 0060 | 203 |
| AB | | | of | the | tee | th, | or i | n su | bsur: | face | reg. | ions | the | rein | . Tl | hus, | che | wing |
| | gum | for | mula | tion | com | pris | ed (| in w | t%): | gum | bas | e 32 | .0, | sucr | ose : | 55.4 | , | |
| | suci | alo | se 0 | .10, | cor | n sy | rup | 2.0, | cal | cium | carl | bona | te 1 | .0, | citr. | ic a | cid | |
| | | | | | | | | alci | | | | | | | | | | 1.0. |
| IT | Chev | vabl | e dr | ug d | eliv | ery | syst | ems | - | - | | | | | - | | | |

Pharmaceutical tablets

(chewable tablets; calcium phosphate salts in

dentifrice oral compns. suitable as a tooth remineralizing agent) 50-21-5, Lactic acid, biological studies 50-70-4, Sorbitol, biological studies 50-81-7, Ascorbic acid, biological studies 50-99-7, Dextrose, biological studies 56-81-5, Glycerin, biological studies 56-84-8, Aspartic acid, biological studies 56-86-0, Glutamic acid, biological studies 57-11-4, Stearic acid, biological studies 57-50-1, Sucrose, biological studies 64-19-7, Acetic acid, biological studies 68-04-2, Sodium Citrate 77-92-9, Citric acid, biological studies 79-09-4, Propionic acid, biological studies 87-69-4, Tartaric acid, biological studies 87-99-0, Xylitol 89-78-1, Menthol 110-15-6, Succinic acid, biological studies 110-17-8, Fumaric acid, biological studies 124-04-9, Adipic acid, biological studies 138-86-3, Orange Flavor 471-34-1, Calcium Carbonate, biological studies 526-95-4, D-Gluconic acid 557-04-0, Magnesium stearate 814-80-2, Calcium Lactate 1306-06-5, Hydroxyapatite 6915-15-7, Malic acid 7722-88-5, Sodium Pyrophosphate 7757-93-9, Dicalcium phosphate 7758-23-8, Monocalcium phosphate 7758-87-4, Tricalcium phosphate 9005-32-7, Alginic acid 10103-46-5, Calcium phosphate 13767-12-9, Tetracalcium phosphate 14096-86-7 22839-47-0, Aspartame 24991-23-9 25513-46-6, Polyglutamic acid 25608-40-6, Polyaspartic acid 26063-13-8, Polyaspartic acid 50813-16-6, Sodium Metaphosphate 55589-62-3, Acesulfame potassium 56038-13-2, Sucralose

RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(calcium phosphate salts in dentifrice oral compns. suitable as a tooth remineralizing agent)

L12 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:814044 CAPLUS <<LOGINID::20080311>>

DOCUMENT NUMBER: 147:173675

TITLE: Pharmaceutical compositions comprising a proton pump

inhibitor and protein component

INVENTOR(S): Phillips, Jeffrev O.

PATENT ASSIGNEE(S): The Curators of the University of Missouri, USA

SOURCE: PCT Int. Appl., 31pp.

CODEN: PIXXD2 Patent

DOCUMENT TYPE: LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

| PAT | ENT : | NO. | | | KIN | D | DATE | | | APPL | ICAT | ION I | NO. | | D | ATE | | |
|-----|-------|------|-----|-----|-----|-----|------|------|-----|------|------|-------|------|------|-----|------|-----|--|
| | | | | | | _ | | | | | | | | | | | | |
| WO | 2007 | 0849 | 64 | | A2 | | 2007 | 0726 | | WO 2 | 007- | US60 | 723 | | 2 | 0070 | 118 | |
| WO | 2007 | 0849 | 64 | | A3 | | 2007 | 1227 | | | | | | | | | | |
| | W: | ΑE, | AG, | AL, | AM, | AT, | AU, | AZ, | BA, | BB, | BG, | BR, | BW, | BY, | BZ, | CA, | CH, | |
| | | CN, | CO, | CR, | CU, | CZ, | DE, | DK, | DM, | DZ, | EC, | EE, | EG, | ES, | FI, | GB, | GD, | |
| | | GE, | GH, | GM, | GT, | HN, | HR, | HU, | ID, | IL, | IN, | IS, | JP, | KE, | KG, | KM, | KN, | |
| | | KP, | KR, | KΖ, | LA, | LC, | LK, | LR, | LS, | LT, | LU, | LV, | LY, | MA, | MD, | MG, | MK, | |
| | | MN, | MW, | MX, | MY, | MZ, | NA, | NG, | NI, | NO, | NZ, | OM, | PG, | PH, | PL, | PT, | RO, | |
| | | RS, | RU, | SC, | SD, | SE, | SG, | SK, | SL, | SM, | SV, | SY, | TJ, | TM, | TN, | TR, | ΤT, | |
| | | TZ, | UA, | UG, | US, | UZ, | VC, | VN, | ZA, | ZM, | ZW | | | | | | | |
| | RW: | AT, | BE, | BG, | CH, | CY, | CZ, | DE, | DK, | EE, | ES, | FI, | FR, | GB, | GR, | HU, | IE, | |
| | | IS, | ΙT, | LT, | LU, | LV, | MC, | NL, | PL, | PT, | RO, | SE, | SI, | SK, | TR, | BF, | ΒJ, | |
| | | CF, | CG, | CI, | CM, | GA, | GN, | GQ, | GW, | ML, | MR, | NE, | SN, | TD, | TG, | BW, | GH, | |
| | | GM. | KE. | LS. | MW. | M7 | NA. | SD. | SI | SZ. | TZ. | HG. | Z.M. | 7.W. | AM. | A7 | BY. | |

KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

US 2006-760256P P 20060119 PRIORITY APPLN. INFO.:

MARPAT 147:173675 OTHER SOURCE(S):

. . . to use of such compns. in treating and preventing diseases and/or AB disorders. Thus, a formulation contained hydrolyzed whey isolate 3000, sucralose 200, dextrose 200, aspartame 200, neotame 3, and pantoprazole 40 mg.

Chewable drug delivery systems

Pharmaceutical tablets

(chewable tablets; pharmaceutical compns.

comprising proton pump inhibitor and protein component)

L12 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:383101 CAPLUS <<LOGINID::20080311>>

DOCUMENT NUMBER: 146:365783

TITLE: Oral compositions containing a salivation inducing

agent INVENTOR(S):

Wynn, David W.; Robinson, Ronni PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 10pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| | FENT | | | | KIN | D | DATE | | | | | ION : | | | | ATE | |
|----|-------|------|-------|-------|------|------|------|------|------|------|------|-------|-----|------|-----|------|-----|
| | 2007 | | | | A1 | | 2007 | 0405 | | US 2 | | | | | | 0050 | |
| WO | 2007 | 0413 | 67 | | A2 | | 2007 | 0412 | | WO 2 | 006- | US38 | 202 | | 2 | 0060 | 928 |
| WO | 2007 | 0413 | 67 | | A3 | | 2007 | 1129 | | | | | | | | | |
| | W: | AE, | AG, | AL, | AM, | AT, | AU, | AZ, | BA, | BB, | BG, | BR, | BW, | BY, | BZ, | CA, | CH, |
| | | CN, | CO, | CR, | CU, | CZ, | DE, | DK, | DM, | DZ, | EC, | EE, | EG, | ES, | FI, | GB, | GD, |
| | | GE, | GH, | GM, | HN, | HR, | HU, | ID, | IL, | IN, | IS, | JP, | KE, | KG, | KM, | KN, | KP, |
| | | KR, | KZ, | LA, | LC, | LK, | LR, | LS, | LT, | LU, | LV, | LY, | MA, | MD, | MG, | MK, | MN, |
| | | MW, | MX, | MY, | MZ, | NA, | NG, | NI, | NO, | NZ, | OM, | PG, | PH, | PL, | PT, | RO, | RS, |
| | | RU, | SC, | SD, | SE, | SG, | SK, | SL, | SM, | SV, | SY, | TJ, | TM, | TN, | TR, | TT, | TZ, |
| | | UA, | UG, | US, | UZ, | VC, | VN, | ZA, | ZM, | ZW | | | | | | | |
| | RW: | AT, | BE, | BG, | CH, | CY, | CZ, | DE, | DK, | EE, | ES, | FI, | FR, | GB, | GR, | HU, | IE, |
| | | IS, | IT, | LT, | LU, | LV, | MC, | NL, | PL, | PT, | RO, | SE, | SI, | SK, | TR, | BF, | ΒJ, |
| | | CF, | CG, | CI, | CM, | GA, | GN, | GQ, | GW, | ML, | MR, | NE, | SN, | TD, | TG, | BW, | GH, |
| | | GM, | KE, | LS, | MW, | MZ, | NA, | SD, | SL, | SZ, | TZ, | UG, | ZM, | ZW, | AM, | AZ, | BY, |
| | | KG, | KZ, | MD, | RU, | TJ, | TM, | AP, | EA, | EP, | OA | | | | | | |
| | Y APP | | | | | | | | | | | | | | | | |
| | | co | atin- | gs ai | opli | ed t | o su | ch p | arti | cles | . or | on ' | the | surf | ace | of s | uch |

coated particles. The particles may be produced into a tablet

form, such as a chewable tablet form, that provides

for the immediate release of the active ingredient. Other oral dosage forms include thin film strips, gummis, foam tabs, and lozenges. Thus, chewable tablet was prepared containing sucralose

powder 10 mg, dextrose monohydrate 956.3 mg, Polyplasdone XL-100

16.7 mg, magnesium stearate 8.0 mg, peppermint flavor 8.0 mg, and salivary inducing agent Succulene. salivation stimulant chewable tablet

Chewable drug delivery systems

Pharmaceutical tablets

(chewable tablets; oral compns. containing salivation-inducing agent)

57-50-1, Sucrose, biological studies 57-55-6, Propylene glycol, biological studies 58-73-1, Diphenhydramine 77-92-9, Citric acid, biological studies 90-82-4, Pseudoephedrine 92-13-7, Pilocarpine 103-90-2, Acetaminophen 113-45-1, Methyl phenidate 125-71-3, Dextromethorphan 132-22-9, Chloropheniramine 471-34-1, Calcium carbonate, biological studies 523-87-5, Dimenhydrinate 532-32-1, Sodium benzoate 557-04-0, Magnesium stearate 569-65-3, Meclizine 5633-20-5, Oxybutynin 9000-07-1, Carrageenan 9003-39-8, Polyplasdone XL 9004-65-3, Hydroxypropylmethylcellulose 14807-96-6, Talc, biological studies 14838-15-4, Phenylpropanolamine 25322-68-3, Polyethylene glycol 25956-17-6, FD&C Red Number 40 34535-98-3D, Phenylcyclopropylamine, derivs. 51481-61-9, Cimetidine 53179-11-6, Loperamide 56038-13-2, Sucralose 66357-35-5, Ranitidine 68844-77-9, Astemizole 76824-35-6, Famotidine 77938-63-7, Dextrose monohydrate 79794-75-5, Loratadine 83799-24-0, Fexofenadine 83881-51-0, Cetirizine 100643-71-8, Desloratadine 107779-84-0D, analogs 930304-00-0, Succulence SN 061022 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (oral compns, containing salivation-inducing agent)

L12 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:544880 CAPLUS <<LOGINID::20080311>>

DOCUMENT NUMBER: 145:34230

TITLE: Medicament comprising fat-based confectionary coating INVENTOR(S): Ream, Ronald L.; Matulewicz, Leonard; Wokas, William

USA PATENT ASSIGNEE(S):

SOURCE: U.S. Pat. Appl. Publ., 15 pp., Cont.-in-part of U.S.

Ser. No. 44,113. CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 22

| I | PAT | ENT I | . OI | | | KIN | D | DATE | | A | PPL | ICAT | ION | NO. | | DATE | |
|-------|-----|-------|------|------|-----|-----|-----|------|------|-----|-----|------|------|-----|--------|--------|-----|
| Ţ | JS | 2006 | 1210 | 92 | | A1 | _ | 2006 | 0608 | U | S 2 | 005- | 2739 | 41 | | 20051 | |
| (| CA | 2431 | 856 | | | A1 | | 1998 | 0604 | C | A 1 | 996- | 2431 | 856 | | 19961 | 127 |
| Ţ | JS | 6355 | 265 | | | В1 | | 2002 | 0312 | U | S 2 | 000- | 5108 | 78 | | 20000 | 223 |
| E | EΡ | 1347 | 746 | | | A1 | | 2003 | 1001 | E | P 2 | 001- | 9535 | 03 | | 20010 | 717 |
| | | R: | AT, | BE, | CH, | DE, | DK, | ES, | FR, | GB, | GR, | IT, | LI, | LU, | NL, SI | E, MC, | PT, |
| | | | IE, | SI, | LT, | LV, | FI, | RO, | MK, | CY, | AL, | TR | | | | | |
| Ţ | JS | 2002 | 1105 | 81 | | A1 | | 2002 | 0815 | U | S 2 | 002- | 4411 | 3 | | 20020 | 109 |
| Ţ | JS | 2004 | 1800 | 07 | | A1 | | 2004 | 0916 | U | S 2 | 003- | 7436 | 09 | | 20031 | 222 |
| Į | JS | 7078 | 052 | | | B2 | | 2006 | 0718 | | | | | | | | |
| PRIOR | ITY | APP: | LN. | INFO | . : | | | | | U | S 1 | 999- | 2868 | 18 | A2 | 19990 | 406 |
| | | | | | | | | | | U | S 2 | 000- | 5108 | 78 | A2 | 20000 | 223 |
| | | | | | | | | | | U | S 2 | 000- | 6313 | 26 | B2 | 20000 | 803 |
| | | | | | | | | | | U | S 2 | 002- | 4411 | 3 | A2 | 20020 | 109 |
| | | | | | | | | | | C | A 1 | 996- | 2271 | 889 | A3 | 19961 | 127 |
| | | | | | | | | | | W | 0 1 | 999- | US29 | 742 | A2 | 19991 | 214 |
| | | | | | | | | | | U | S 2 | 000- | 6715 | 52 | B1 | 20000 | 927 |
| | | | | | | | | | | W | 0 2 | 001- | US22 | 360 | W | 20010 | 717 |

. . 1b and water 215 1b. Coating was prepared containing acetaminophen AB 0.3490 g, peppermint flavor 0.0072 g, menthol flavor 0.0062 g, dextrose 1.4200 g, sucralose 0.0030 g, aspartame 0.0062

and glucose 0.2080. The coating can be used to coat a consumable center.

IT Drug delivery systems

(tablets, chewable; medicament comprising fat-based

confectionary coating)

50-70-4P, Sorbitol, biological studies 50-99-7P, Dextrose, biological studies 56-81-5P, Glycerin, biological studies 77-92-9P, Citric acid, biological studies 90-80-2P, Glucono δ -lactone 103-90-2P, Acetaminophen 121-32-4P, Ethyl vanillin 121-33-5P, Vanillin 471-34-1P, Calcium carbonate, biological studies 527-07-1P, Sodium gluconate 1405-86-3P 9005-25-8P, Starch, biological studies 104859-78-1P, Sweetose 4300

RL: IMF (Industrial manufacture); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(medicament comprising fat-based confectionary coating)

81-07-2P, Saccharin 22839-47-0P, Aspartame 55589-62-3P, Acesulfame-k 56038-13-2P, Sucralose RL: IMF (Industrial manufacture); THU (Therapeutic use); BIOL (Biological

study); PREP (Preparation); USES (Uses)

(sweetener; medicament comprising fat-based confectionary coating)

L12 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:76246 CAPLUS <<LOGINID::20080311>> DOCUMENT NUMBER: 142:162634

TITLE:

Chewable tablets comprising alginic acid and a carbonate precursor

INVENTOR(S): Adusumilli, Prasad; Kim, Chungbin; Lech, Stanley J.;

Mehta, Naresh I.; Dinner, Dara L.

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 81 pp. CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English FAMILY ACC. NUM. COUNT: 1

| PA7 | ENT : | NO. | | | KIN | D | DATE | | | APPL | ICAT | ION : | . OP | | D. | ATE | |
|-----|-------|-------|-----|-----|-----|-----|------|------|-----|------|------|-------|------|-----|-----|------|-----|
| | | | | | | - | | | | | | | | | | | |
| WO | 2005 | 0071 | 0.5 | | A2 | | 2005 | 0127 | | WO 2 | 004- | US22 | 082 | | 2 | 0040 | 709 |
| WO | 2005 | 0071 | 05 | | A3 | | 2005 | 0519 | | | | | | | | | |
| | W: | ΑE, | AG, | AL, | AM, | AT, | AU, | AZ, | BA, | BB, | BG, | BR, | BW, | BY, | BZ, | CA, | CH, |
| | | CN, | CO, | CR, | CU, | CZ, | DE, | DK, | DM, | DZ, | EC, | EE, | EG, | ES, | FΙ, | GB, | GD, |
| | | GE, | GH, | GM, | HR, | HU, | ID, | IL, | IN, | IS, | JP, | KE, | KG, | KP, | KR, | ΚZ, | LC, |
| | | LK, | LR, | LS, | LT, | LU, | LV, | MA, | MD, | MG, | MK, | MN, | MW, | MX, | MZ, | NA, | NI, |
| | | NO, | NZ, | OM, | PG, | PH, | PL, | PT, | RO, | RU, | SC, | SD, | SE, | SG, | SK, | SL, | SY, |
| | | TJ, | TM, | TN, | TR, | TT, | TZ, | UA, | UG, | US, | UZ, | VC, | VN, | YU, | ZA, | ZM, | ZW |
| | RW: | BW, | GH, | GM, | KE, | LS, | MW, | MZ, | NA, | SD, | SL, | SZ, | TZ, | UG, | ZM, | ZW, | AM, |
| | | AZ, | BY, | KG, | KZ, | MD, | RU, | ΤJ, | TM, | ΑT, | BE, | BG, | CH, | CY, | CZ, | DE, | DK, |
| | | EE, | ES, | FI, | FR, | GB, | GR, | HU, | ΙE, | ΙT, | LU, | MC, | NL, | PL, | PT, | RO, | SE, |
| | | SI, | SK, | TR, | BF, | ΒJ, | CF, | CG, | CI, | CM, | GA, | GN, | GQ, | GW, | ML, | MR, | NE, |
| | | SN, | TD, | TG | | | | | | | | | | | | | |
| CA | 2531 | 065 | | | A1 | | 2005 | 0127 | | CA 2 | 004- | 2531 | 065 | | 2 | 0040 | 709 |
| US | 2005 | 2020: | 84 | | A1 | | 2005 | 0915 | | US 2 | 004- | 8882 | 42 | | 2 | 0040 | 709 |
| EP | 1648 | 411 | | | A2 | | 2006 | 0426 | | EP 2 | 004- | 7568 | 33 | | 2 | 0040 | 709 |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR US 2007178150 US 2006-583521 20060109 A1 20070802 MX 2006PA00417 A 20060317 MX 2006-PA417 20060110 P 20030710 PRIORITY APPLN. INFO.: US 2003-486033P WO 2004-US22082 W 20040709

- Chewable tablets comprising alginic acid and a carbonate precursor
- A pharmaceutical composition in the form of a chewable tablet for the suppression of gastric reflux comprising an alginic acid or salt thereof, a water-soluble carbonate radical precursor, a calcium. . .
- alginate carbonate precursor calcium salt antacid chewable tablet
- ТТ Antacids

Flavoring materials

Sweetening agents

(chewable tablets comprising alginic acid,

carbonate precursor and calcium salt)

Caseins, biological studies

Gelatins, biological studies

Hydrocarbon oils

Polyoxyalkylenes, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (chewable tablets comprising alginic acid,

carbonate precursor and calcium salt)

Polyphosphoric acids

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(sodium salts; chewable tablets comprising alginic

acid, carbonate precursor and calcium salt)

Drug delivery systems

(tablets, chewable; chewable

tablets comprising alginic acid, carbonate precursor and

calcium salt)

9003-01-4D, crosslinked

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Carbomer; chewable tablets comprising alginic

acid, carbonate precursor and calcium salt)

50-70-4, Sorbitol, biological studies 50-99-7, Dextrose, biological studies 57-48-7, Fructose, biological studies Sucrose, biological studies 63-42-3, Lactose 69-65-8, Mannitol 69-79-4, Maltose 79-41-4D, Methacrylic acid, derivs., polymers 81-07-2, Saccharin 87-99-0, Xylitol 144-55-8, Sodium bicarbonate, biological studies 298-14-6, Potassium bicarbonate 463-79-6D, Carbonic acid, alkali and alkaline earth metal salts 471-34-1, Calcium carbonate, biological studies 546-93-0, Magnesium carbonate 585-88-6, Maltitol 814-80-2, Calcium lactate 1309-42-8, Magnesium hydroxide 1309-48-4, Magnesium oxide, biological studies 1336-00-1 1592-23-0, Calcium stearate 7440-70-2D, Calcium, citrate maleate complexes 7440-70-2D, Calcium, salts 7632-05-5, Sodium phosphate 7693-13-2, Calcium citrate 9000-01-5, Gum arabic 9000-07-1, Carrageenan 9000-30-0, Guar gum 9000-65-1, Tragacanth 9000-69-5, Pectin 9002-89-5, Polyvinyl alcohol 9003-39-8, Povidone 9004-32-4, Sodium carboxymethyl cellulose 9004-64-2, 9004-63-0, Hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methyl cellulose 9004-67-5, Methyl cellulose 9005-25-8, Starch, biological studies

9005-32-7, Alginic acid 9050-36-6, Maltodextrin 10103-46-5, Calcium

phosphate 11137-98-7, Magnesium aluminate 14807-96-6, Talc, biological studies 16068-46-5, Potassium phosphate 18694-07-0D, Hexametaphosphoric acid, alkali and alkaline earth metal salts 21645-51-2, Aluminum hydroxide, biological studies 22839-47-0, Aspartame 25322-68-3, Polyethylene oxide 34938-90-4, Calcium maleate 39366-43-3, Aluminum magnesium hydroxide 55589-62-3, Acesulfame-K 56038-13-2, Sucralose 68424-04-4, Polydextrose 106392-12-5, Poloxamer 126040-58-2, Calcium polycarbophil RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (chewable tablets comprising alginic acid, carbonate precursor and calcium salt) 9004-34-6, Cellulose, biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (microcryst.; chewable tablets comprising alginic acid, carbonate precursor and calcium salt)

L12 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:1001577 CAPLUS <<LOGINID::20080311>>

DOCUMENT NUMBER: 140:47520

TITLE: Chewable oral contraceptive

Boissonneault, Roger M.; Devries, Tina M. INVENTOR(S):

PATENT ASSIGNEE(S): Galen Chemicals Limited, Ire.

SOURCE: U.S., 9 pp., Cont.-in-part of U.S. Ser. No. 286,908.

CODEN: USXXAM Patent

DOCUMENT TYPE:

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|--------------|---------------------|--------------------|
| | | | | |
| US 6667050 | B1 | 20031223 | US 2001-879028 | 20010612 |
| PRIORITY APPLN. INFO.: | | | US 1999-286908 | A2 19990406 |
| REFERENCE COUNT: | 10 | THERE ARE 10 | CITED REFERENCES A | AVAILABLE FOR THIS |
| | | RECORD. ALL | CITATIONS AVAILABLE | IN THE RE FORMAT |

AB The present invention relates to a chewable, palatable oral contraceptive tablet, comprising an oral contraceptive agent, a chewable carrier suitable for human consumption, and not comprising a ferrocene compound, as well. . .

IT Drug delivery systems

(tablets; chewable oral contraceptive) 50-70-4, Sorbitol, biological studies 50-99-7, Dextrose, ΙT biological studies 57-48-7, Fructose, biological studies 57-50-1, Sucrose, biological studies 63-42-3, Lactose 69-65-8, Mannitol

87-99-0, Xvlitol 471-34-1, Calcium carbonate, biological studies 557-04-0, Magnesium stearate 7757-93-9, Dicalcium phosphate 9003-39-8, Povidone 9005-25-8, Corn starch, biological studies 9050-36-6,

Maltodextrin 9063-38-1, Sodium starch glycolate 56038-13-2, Sucralose

RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (chewable oral contraceptive)

L12 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:737151 CAPLUS <<LOGINID::20080311>>

DOCUMENT NUMBER: 139:250306 TITLE: Soft tablets containing high molecular weight

polvethylene oxide

Luber, Joseph; Bunick, Frank J. INVENTOR(S): PATENT ASSIGNEE(S): McNeil-PPC, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 7 pp. DOCUMENT TYPE:

Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|--------------|----------------------|-------------------|
| | | | | |
| US 2003175336 | A1 | 20030918 | US 2002-97000 | 20020313 |
| US 6753009 | B2 | 20040622 | | |
| CA 2421685 | A1 | 20030913 | CA 2003-2421685 | 20030312 |
| PRIORITY APPLN. INFO.: | | | US 2002-97000 | A 20020313 |
| REFERENCE COUNT: | 24 | THERE ARE 24 | 4 CITED REFERENCES A | VAILABLE FOR THIS |
| | | RECORD. ALL | CITATIONS AVAILABLE | IN THE RE FORMAT |

. . . oxide (average mol. weight 5,000,000), vitamin E granules 13.3, erythritol 100, crospovidone 25, colorant 2.5, coated ibuprofen 282.1,

flavors 15, sucralose 10, dextrose monohydrate 658, and lubricants 7.5 parts.

Drug delivery systems

(tablets, chewable; immediate-release matrixes

containing high mol. weight PEG and antioxidants for soft tablets)

L12 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:833295 CAPLUS <<LOGINID::20080311>>

DOCUMENT NUMBER: 137:329468

TITLE: Over-coated chewing gum formulations

INVENTOR(S): Ream, Ronald L.; Greenberg, Michael J.; Wokas, William

J.; Corriveau, Christine L.

PATENT ASSIGNEE(S): USA SOURCE: U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S.

6,355,265.

CODEN: USXXCO Patent

English LANGUAGE:

FAMILY ACC. NUM. COUNT: 22

PATENT INFORMATION:

DOCUMENT TYPE:

| PATENT NO. | KIND DATE | APPLICATION NO. | DATE | | | | |
|-----------------|-----------------|---------------------|-----------------|--|--|--|--|
| | | | | | | | |
| US 2002159956 | A1 20021031 | US 2001-990628 | 20011113 | | | | |
| CA 2431856 | A1 19980604 | CA 1996-2431856 | 19961127 | | | | |
| WO 2000035296 | A1 20000622 | WO 1999-US29742 | 19991214 | | | | |
| W: AE, AL, AM, | AT, AU, AZ, BA, | BB, BG, BR, BY, CA, | CH, CN, CR, CU, | | | | |
| CZ, DE, DK, | DM, EE, ES, FI, | GB, GD, GE, GH, GM, | HR, HU, ID, IL, | | | | |
| IN, IS, JP, | KE, KG, KP, KR, | KZ, LC, LK, LR, LS, | LT, LU, LV, MA, | | | | |
| MD, MG, MK, | MN, MW, MX, NO, | NZ, PL, PT, RO, RU, | SD, SE, SG, SI, | | | | |
| SK, SL, TJ, | TM, TR, TT, TZ, | UA, UG, US, UZ, VN, | YU, ZA, ZW | | | | |
| RW: GH, GM, KE, | LS, MW, SD, SL, | SZ, TZ, UG, ZW, AT, | BE, CH, CY, DE, | | | | |
| DK, ES, FI, | FR, GB, GR, IE, | IT, LU, MC, NL, PT, | SE, BF, BJ, CF, | | | | |
| CG, CI, CM, | GA, GN, GW, ML, | MR, NE, SN, TD, TG | | | | | |
| US 6355265 | B1 20020312 | US 2000-510878 | 20000223 | | | | |

```
EP 1347746
                             A1 20031001 EP 2001-953503
          R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
               IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     US 2004180007 A1 20040916
US 7078052 B2 20060718
                                                   US 2003-743609
                                                                               20031222
                                                    US 1999-286818 A2 19990406
WO 1999-US29742 W 19991214
US 2000-510878 A2 2000023
CA 1996-2271889 A3 19961127
US 1998-1123899 P 19981217
US 1998-1123899 P 19981215
US 1999-389211 A2 1999092
US 1999-389211 A2 1999092
WO 2001-US22360 W 20010717
PRIORITY APPLN. INFO.:
     . . . caffeine chewing gum pieces (sticks), which were chewed for 15
     min and removed. The reference treatment was one 100 mg chewable
     No-Doz tablet, which was chewed and swallowed. The caffeine
     chewing gum pieces appear to have a much faster rate of absorption that
     the No-Doz chewable tablets. The areas and peak
     concns. of the chewing gum were less than half that of No-Doz even though
     the gum. . .
     50-99-7, Dextrose, biological studies 56-40-6, Glycine,
biological studies 57-48-7, Fructose, biological studies 81-07-2,
Saccharin 87-99-0, Xylitol 90-80-2, Glucono-8-lactone 90-82-4,
      Pseudoephedrine 103-90-2, Acetaminophen 121-32-4, Ethyl vanillin
      121-33-5, Vanillin 527-07-1, Sodium gluconate 585-88-6, Maltitol
     1405-86-3 4468-02-4, Zinc gluconate 4940-11-8, Ethyl maltol 9004-10-8, Insulin, biological studies 22839-47-0, Aspartame
     55589-62-3, Acesulfame-k 56038-13-2, Sucralose 64519-82-0.
      Isomalt
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
         (over-coated chewing gum formulations with improved drug
         bioavailability)
L12 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:674573 CAPLUS <<LOGINID::20080311>>
DOCUMENT NUMBER:
                             137:206554
TITLE:
                            Chewable tablets containing
                            hydrate excipients.
INVENTOR(S):
INVENTOR(S):

PATENT ASSIGNEE(S):

McNeil-PPC, Inc., USA

Compared Appl. Publ.,
                            Bunick, Frank J.; Luber, Joseph
                            U.S. Pat. Appl. Publ., 5 pp.
                             CODEN: USXXCO
DOCUMENT TYPE:
                            Patent
LANGUAGE:
                            English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
     PATENT NO. KIND DATE APPLICATION NO. DATE
     US 2002122822 A1 20020905
US 6814978 B2 20041109
US 2003175339 A1 20030918
                                                 US 2000-752601
                                                                               20001229
                                                   US 2003-413804 20030415
US 2000-752601 A1 20001229
PRIORITY APPLN. INFO.:
                      18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS
REFERENCE COUNT:
```

AB

TT

Compression

Particle size

excipients)

sodium

ACCESSION NUMBER:

FAMILY ACC. NUM. COUNT: 22 PATENT INFORMATION:

```
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
    Chewable tablets containing hydrate excipients.
    . . . tablet for a sufficient time to decrease the hardness of the
    tablet by at least about 20%. A composition contained sucralose 8.0,
    coated ibuprofen (69.0%) 140.6, flavor 10.0, dextrose
    monohydrate 850.0, Crospovidone 15.0, and Mg stearate 7.5.
    tablet chewable hydrate excipient
    Hardness (mechanical)
       (chewable tablets containing hydrate excipients)
    Drug delivery systems
        (tablets, chewable; chewable
       tablets containing hydrate excipients)
    9003-39-8D, crosslinked
    RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL
    (Biological study); USES (Uses)
        (Crospovidone; chewable tablets containing hydrate
    5949-29-1, Citric acid monohydrate 7782-85-6, Phosphoric acid, disodium
    salt, heptahydrate 7789-77-7, Dibasic calcium phosphate dihydrate
    9004-34-6, Cellulose, biological studies 9004-53-9, Dextrin 9005-25-8,
    Starch, biological studies 9005-32-7, Alginic acid 9050-36-6,
    Maltodextrin 9063-38-1, Sodium starch glycolate 10028-24-7, Phosphoric
    acid, disodium salt, dihydrate 10039-32-4, Phosphoric acid, disodium
    salt, dodecahydrate 10049-21-5, Monosodium phosphate monohydrate
    13472-35-0, Monosodium phosphate dihydrate 14431-43-7, Dextrose
    monohydrate 64044-51-5, Lactose monohydrate
                                                   74811-65-7, Croscarmellose
    RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL
    (Biological study); USES (Uses)
       (chewable tablets containing hydrate excipients)
    58-73-1, Diphenhydramine 90-82-4, Pseudoephedrine
                                                         103-90-2,
    Acetaminophen 113-92-8, Chlorpheniramine 125-71-3, Dextromethorphan
    471-34-1, Calcium carbonate, biological studies 546-93-0, Magnesium
    carbonate 1309-42-8, Magnesium hydroxide 1309-48-4, Magnesium oxide,
    biological studies 15687-27-1, Ibuprofen 21645-51-2, Aluminum
    hydroxide, biological studies
    RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (chewable tablets containing hydrate excipients)
L12 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
                        2002:616210 CAPLUS <<LOGINID::20080311>>
                        137:174936
                        Over-coated product including consumable center and
                        medicament
```

```
DOCUMENT NUMBER:
TITLE:
INVENTOR(S):
                        Ream, Ronald L.; Matulewicz, Leonard; Wokas, William
                         J.
PATENT ASSIGNEE(S):
                        USA
SOURCE:
                         U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S.
                         Ser. No. 631,326.
                         CODEN: USXXCO
DOCUMENT TYPE:
                        Patent
LANGUAGE:
                        English
```

1c

| | KIND DATE | | DATE | | | | | | | | | | |
|--|---|--|--|--|--|--|--|--|--|--|--|--|--|
| US 2002110581
CA 2431856
US 6355265
EP 1347746
R: AT, BE, CH, | | EP 2001-953503
B, GR, IT, LI, LU, NL, | | | | | | | | | | | |
| US 2004180007
US 7078052 | A1 20040916
B2 20060718 | US 2003-743609 | 20031222 | | | | | | | | | | |
| US 2006141008
US 2006121092
US 2006121093 | A1 20060629
A1 20060608
A1 20060608 | US 2003-743609 US 2005-269980 US 2005-273941 US 2005-273942 US 1999-286818 A 18 2000-510878 | 20051109
20051115
20051115 | | | | | | | | | | |
| PRIORITY APPLN. INFO.: | | US 2000-631326 A
CA 1996-2271889 A
WO 1999-US29742 A | 2 20000803
3 19961127
2 19991214
1 20000927 | | | | | | | | | | |
| individual are pro-
comprises a chewab
medicament or agent | Methods for manufacturing products for delivering a medicament or agent to an
individual are provided. The product, e,g, a tablet or gum,
comprises a chewable consumable center and a coating containing a
medicament or agent, a high-intensity sweetener and a taste-masking agent. | | | | | | | | | | | | |
| By chewing the | | | | | | | | | | | | | |
| confectionary center and drug coating) T7-92-9, Citric acid, biological studies 81-07-2, Saccharin 87-99-0, Xylitol 89-78-1, Menthol 121-33-5, Vanillin 22839-47-0, Aspartame 55589-62-3, Acesulfame-k 56038-13-2, Sucralose RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (USes) | | | | | | | | | | | | | |
| (chewing compns. based on confectionary center and drug coating) 150-70-4, Sorbitol, biological studies 50-99-7, Dextrose, biological studies 56-81-5, Glycerin, biological studies 90-82-4, Pseudoephedrine 103-90-2, Acetaminophen 471-34-1, Calcium carbonate, biological studies 9004-10-8, Insulin, biological studies 9050-36-6, Maltodextrin 97444-70-7, Talha gum RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (chewing compns. based on confectionary center and drug coating) | | | | | | | | | | | | | |
| L12 ANSWER 12 OF 14 CA
ACCESSION NUMBER:
DOCUMENT NUMBER:
TITLE: | 2002:143205 CAPL
136:189384
Oral delivery of p | US < <loginid::20080311>
pharmaceuticals via enc</loginid::20080311> | | | | | | | | | | | |
| INVENTOR(S): PATENT ASSIGNEE(S): SOURCE: | Battey, Alyce S.;
USA
U.S. Pat. Appl. Po
CODEN: USXXCO | | | | | | | | | | | | |
| DOCUMENT TYPE:
LANGUAGE: | DOCUMENT TYPE: Patent | | | | | | | | | | | | |

FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION:

AB

```
PATENT NO. KIND DATE APPLICATION NO. DATE
      WS 2002022057 A1 20020221 US 2001-931793 20010817 WO 2003009834 A1 20030206 WO 2001-US25791 20010817
          W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
               CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
               HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
               LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
               RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
               VN, YU, ZA, ZW
           RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
               DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
               BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
      AU 2001285022 A1 20030217 AU 2001-255022 20010817

NITY APPLN. INFO.: WS 2000-225877P P 20000817

WO 2001-USS25791 W 2010817
PRIORITY APPLN. INFO.:
     . . . Benefits of this invention include portability and the ability to
      take pharmaceuticals without water and without the off taste of
      chewable tablets, thereby leading to increased patient
      compliance. For example, diphenhydramine, an antihistamine and sedative,
      was encapsulated via spray drying. Diphenhydramine hydrochloride. . .
     50-70-4, Sorbitol, biological studies 50-99-7, Dextrose, biological studies 57-48-7, Fructose, biological studies
      Surrose, biological studies 63-42-3, Lactose 69-65-8, Mannitol 69-79-4, Maltose 81-07-2, Saccharin 87-99-0, Xylitol 100-88-9, Cyclamate 128-44-9, Saccharin sodium 3844-45-9, FD&C Blue 1
      9050-36-6, Maltodextrin 22839-47-0, Aspartame 55589-62-3, Acesulfame
      potassium 56038-13-2, Sucralose 165450-17-9, Neotame
      RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
         (drug encapsulation for dissoln. in and absorption through oral cavity)
L12 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:300547 CAPLUS <<LOGINID::20080311>>
DOCUMENT NUMBER:
                            134:316140
                          Pharmaceutical compositions containing neotame
TITLE:
INVENTOR(S): Ponakala, Subbarao V.

PATENT ASSIGNEE(S): The Nutrasweet Company, USA
SOURCE: PCT Int. Appl., 21 pp.
INVENTOR(S):
                             CODEN: PIXXD2
DOCUMENT TYPE:
LANGUAGE:
                            Patent
                            English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
      PATENT NO. KIND DATE APPLICATION NO. DATE
      WO 2001028590 A2 20010426 WO 2000-US28731
WO 2001028590 A3 20080103
                                                                               20001018
          AS 20001028590

M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NO, NZ, PL, PT, RO, RU,
               SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
           RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
```

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG, AP, EA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, EP, OA

PRIORITY APPLN. INFO.: US 1999-160305P P 19991019

IT Drug delivery systems

(tablets, chewable; pharmaceutical compns. containing

50-70-4, Sorbitol, biological studies 50-99-7, Dextrose, biological studies 57-48-7, Fructose, biological studies 57-50-1, Sucrose, biological studies 57-50-1D, Sucrose, derivs. 58-86-6, Xylose, biological studies 59-23-4, Galactose, biological studies 69-65-8, Mannitol 69-79-4, Maltose 81-07-2, Saccharin 87-99-0, Xylitol 100-88-9, Cyclamate 100-88-9D, Cyclamate, derivs. 103-90-2, Acetaminophen 471-34-1, Calcium carbonate, biological studies 557-04-0, Magnesium stearate 608-66-2, Galactito1 3458-28-4, Mannose 5556-48-9, Ribulose 9005-25-8D, Starch, partially hydrolyzed, biological studies 9050-36-6, Maltodextrin 20702-77-6, Neohesperidin dihydrochalcone 22839-47-0, Aspartame 27215-73-2 33665-90-6, Acesulfame 53956-04-0, Monoammonium glycyrrhizate 56038-13-2, Sucralose 64519-82-0, Isomalt 80863-62-3, Alitame 165450-17-9, Neotame 188627-84-1, Multivitamins 335329-29-8 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceutical compns. containing neotame)

L12 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:197386 CAPLUS <<LOGINID::20080311>>

DOCUMENT NUMBER: 128:275080

TITLE: Directly compressible lactitol granules and tablets

INVENTOR(S): Pearson, Julita; Olinger, Philip

PATENT ASSIGNEE(S): Xyrofin Oy, Finland; Pearson, Julita; Olinger, Philip

SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

| PA' | TENT : | NO. | | | KIN | D | DATE | | | APPL | ICAT | ION: | NO. | | Di | ATE | | |
|-----|--------|-------------------|-------------------|-------------------|-------------|-------------------|------------|------------|---------------|------------|--------------------------|------------|------------|------------|------------|------------|------------|---|
| WO | 9811 | 11878 | | | A1 19980326 | | | | WO 1997-FI548 | | | | 19970916 < | | | | | |
| | W: | DK,
KZ,
PL, | EE,
LC,
PT, | ES,
LK,
RO, | FI,
LR, | GB,
LS,
SD, | GE,
LT, | GH,
LU, | HU,
LV, | ID,
MD, | BY,
IL,
MG,
SL, | IS,
MK, | JP,
MN, | KE,
MW, | KG,
MX, | KP,
NO, | KR,
NZ, | |
| | RW: | GH,
GB, | KE,
GR, | LS,
IE, | MW,
IT, | SD,
LU, | | NL, | | | BE,
BF, | | | | | | | |
| US | 5846 | 568 | | | A | | 1998 | 1208 | | US 1 | 996- | 7158 | 25 | | 1 | 9960 | 919 | < |
| CA | 2263 | 495 | | | A1 | | 1998 | 0326 | | CA 1 | 997- | 2263 | 495 | | 15 | 9970 | 916 | < |
| AU | 9743 | 042 | | | A | | 1998 | 0414 | | AU 1 | 997- | 4304 | 2 | | 1 | 9970 | 916 | < |
| AU | 7290 | 40 | | | B2 | | 2001 | 0125 | | | | | | | | | | |
| EP | 9383 | 01 | | | A1 | | 1999 | 0901 | | EP 1 | 997- | 9190 | 75 | | 1 | 9970 | 916 | < |
| EP | 9383 | 01 | | | B1 | | 2002 | 1218 | | | | | | | | | | |
| EP | 9383 | 01 | | | B2 | | 2006 | 0222 | | | | | | | | | | |
| | R: | AT. | BE. | CH. | DE. | DK. | ES. | FR. | GB. | GR. | TT. | LT. | LU. | NI | SE. | MC. | PT. | |

```
IE, SI, LT, FI

JP 2001502667 T 20010227 JP 1998-514321 19970916 <--
RU 2187999 C2 20020827 RU 1999-105852 19970916 <--
AT 229797 T 20030115 AT 1997-919075 19970916 <--
ES 2187769 T3 20030616 ES 1997-919075 19970916 <--
KR 2000036234 A 20000626 KR 1999-702316 19990318 <--
RITY APPLN. INFO:

US 1996-715825 A 19960919
W0 1997-FI548 W 19970916
PRIORITY APPLN. INFO.:
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
      PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 9811878 A1 19980326 WO 1997-FI548 19970916 <--
            W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
                 DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR,
                 KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ,
                 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG,
                 US, UZ, VN, YU, ZW
            RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
                 GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
                 GN, ML, MR, NE, SN, TD, TG
      GN, ML, MR, NS, SN, TD, TG
US 5846568 A 19981208 US 1996-715825 19960919 <--
CA 2263495 A1 19980326 CA 1997-2263495 19970916 <--
AU 9743042 A 19980414 AU 1997-43042 19970916 <--
AU 729040 B2 20010125
EP 938301 A1 19990901 EP 1997-919075 19970916 <--
EP 938301 B1 20021218
EP 938301 B2 20060222
           938301 B2 20060222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
                IE, SI, LT, FI
      JP 2001502667 T 20010227 JP 1998-514321 RU 2187999 C2 20020827 RU 1999-105852 AT 229797 T 20030115 AT 1997-919075 E5 2187769 T3 20030616 E5 1997-919075 KR 2000036234 A 20000626 KR 1999-702316
                                                                                        19970916 <--
                                                                                        19970916 <--
                                                                                        19970916 <--
                                                                                        19970916 <--
                                                                                        19990318 <--
ST cellulose gum lactitol tablet granule; lactitol direct
      compression tablet granule
      63-42-3, Lactose 69-65-8, Mannitol 81-07-2, Saccharin 87-99-0,
      Xvlitol 100-88-9, Cvclamate 585-86-4, Lactitol 9000-01-5, Gum arabic
      9000-11-7D, salts 9003-39-8, Polyvinylpyrrolidone 9004-32-4
      9004-64-2 9005-25-8D, Starch, hydrolyzates, hydrogenated, biological
      studies 9050-36-6, Maltodextrin 13241-33-3, Neohesperidin
      55589-62-3, Acesulfame K 56038-13-2, Sucralose 57817-89-7,
      Stevioside 81025-03-8, Lactitol dihydrate 81025-04-9, Lactitol monohydrate 132339-63-0, Lactitol trihydrate
      RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
           (directly compressible lactitol granules and tablets)
=> log h
COST IN U.S. DOLLARS
                                                                 SINCE FILE
                                                                                    TOTAL
                                                                       ENTRY SESSION
127.71 127.92
FULL ESTIMATED COST
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION
```

CA SUBSCRIBER PRICE -11.20 -11.20

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 14:14:03 ON 11 MAR 2008